Clinical and Economic Utility of BTK Inhibitors in CLL

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

Experts evaluate the value of BTK inhibitors in CLL treatment.

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

A panel of experts discuss optimizing therapy sequencing in CLL.

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

A panel of experts discuss combination regimens with BTK inhibitors.

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of experts discuss navigating access challenges in CLL treatment.

A group of experts discuss implications for patient access in CLL.

A panel of specialists discuss patient access advocacy for BTK inhibitors.

Experts discuss future directions of BTK inhibitors.